TY - JOUR
T1 - Chronic Neutrophilic Leukemia
T2 - Advances in Diagnosis, Genetic Insights, and Management Strategies
AU - Elbaz Younes, Ismail
AU - Mroz, Pawel
AU - Tashakori, Mehrnoosh
AU - Hamed, Amira
AU - Sen, Siddhartha
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/1
Y1 - 2025/1
N2 - CNL is a rare subtype of MPNs characterized by persistent neutrophilia, bone marrow hypercellularity, and specific genetic mutations, particularly in the CSF3R gene. Advances in molecular diagnostics have greatly enhanced our understanding of CNL, distinguishing it from other myeloproliferative disorders and refining diagnostic criteria. This review provides an updated overview of CNL, focusing on breakthroughs in genetic profiling, including novel mutations with potential prognostic value and implications for targeted therapy. We discuss current management strategies, emphasizing the role of JAK inhibitors, allogeneic stem cell transplantation, and evolving investigational treatments. Challenges in early diagnosis, therapeutic resistance, and future directions in research are also addressed, underscoring the need for a personalized medicine approach to improve outcomes for patients with CNL.
AB - CNL is a rare subtype of MPNs characterized by persistent neutrophilia, bone marrow hypercellularity, and specific genetic mutations, particularly in the CSF3R gene. Advances in molecular diagnostics have greatly enhanced our understanding of CNL, distinguishing it from other myeloproliferative disorders and refining diagnostic criteria. This review provides an updated overview of CNL, focusing on breakthroughs in genetic profiling, including novel mutations with potential prognostic value and implications for targeted therapy. We discuss current management strategies, emphasizing the role of JAK inhibitors, allogeneic stem cell transplantation, and evolving investigational treatments. Challenges in early diagnosis, therapeutic resistance, and future directions in research are also addressed, underscoring the need for a personalized medicine approach to improve outcomes for patients with CNL.
KW - CSF3R
KW - T618I
KW - chronic neutrophilic leukemia
KW - molecular pathogenesis
KW - myeloproliferative neoplasms
KW - targeted therapy
UR - https://www.scopus.com/pages/publications/85215692718
UR - https://www.scopus.com/pages/publications/85215692718#tab=citedBy
U2 - 10.3390/cancers17020227
DO - 10.3390/cancers17020227
M3 - Review article
C2 - 39858009
AN - SCOPUS:85215692718
SN - 2072-6694
VL - 17
JO - Cancers
JF - Cancers
IS - 2
M1 - 227
ER -
